Diagnostic potential of circulating cell-free microRNAs for community-acquired pneumonia and pneumonia-related sepsis.
biomarker signature
cell-free microRNAs
community-acquired pneumonia
extracellular vesicles
sepsis
small RNA sequencing
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
09
04
2020
revised:
11
08
2020
accepted:
17
08
2020
pubmed:
12
9
2020
medline:
7
5
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
Cell-free microRNAs (miRNAs) are transferred in disease state including inflammatory lung diseases and are often packed into extracellular vesicles (EVs). To assess their suitability as biomarkers for community-acquired pneumonia (CAP) and severe secondary complications such as sepsis, we studied patients with CAP (n = 30), sepsis (n = 65) and healthy volunteers (n = 47) subdivided into a training (n = 67) and a validation (n = 75) cohort. After precipitating crude EVs from sera, associated small RNA was profiled by next-generation sequencing (NGS) and evaluated in multivariate analyses. A subset of the thereby identified biomarker candidates was validated both technically and additionally by reverse transcription quantitative real-time PCR (RT-qPCR). Differential gene expression (DGE) analysis revealed 29 differentially expressed miRNAs in CAP patients when compared to volunteers, and 25 miRNAs in patients with CAP, compared to those with sepsis. Sparse partial-least discriminant analysis separated groups based on 12 miRNAs. Three miRNAs proved as a significant biomarker signature. While expression levels of miR-1246 showed significant changes with an increase in overall disease severity from volunteers to CAP and to sepsis, miR-193a-5p and miR-542-3p differentiated patients with an infectious disease (CAP or sepsis) from volunteers. Cell-free miRNAs are potentially novel biomarkers for CAP and may help to identify patients at risk for progress to sepsis, facilitating early intervention and treatment.
Identifiants
pubmed: 32916773
doi: 10.1111/jcmm.15837
pmc: PMC7578906
doi:
Substances chimiques
Circulating MicroRNA
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12054-12064Informations de copyright
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Curr Opin Pulm Med. 2018 May;24(3):227-236
pubmed: 29432220
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8
pubmed: 21383194
J Extracell Vesicles. 2019 Sep 27;8(1):1670935
pubmed: 31632620
Theranostics. 2018 May 23;8(12):3348-3365
pubmed: 29930734
BMC Genomics. 2017 Jan 7;18(1):50
pubmed: 28061744
J Extracell Vesicles. 2018 Jun 04;7(1):1481321
pubmed: 29887978
BMC Med Genomics. 2015 Oct 14;8:61
pubmed: 26462558
Curr Pharm Des. 2003;9(27):2177-90
pubmed: 14529398
J Extracell Vesicles. 2015 May 14;4:27066
pubmed: 25979354
Sci Rep. 2015 Mar 24;5:9430
pubmed: 25800946
J Nephrol. 2019 Oct;32(5):699-707
pubmed: 30523563
Am J Respir Crit Care Med. 2017 Dec 1;196(11):1422-1433
pubmed: 28809518
RNA. 2010 May;16(5):991-1006
pubmed: 20360395
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
Clin Chim Acta. 2016 Nov 1;462:140-145
pubmed: 27662812
J Cell Mol Med. 2017 Oct;21(10):2403-2411
pubmed: 28382754
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
Crit Care. 2016 Feb 16;20:41
pubmed: 26880194
J Infect Dis. 2020 Jan 2;221(2):325-335
pubmed: 31617573
Genome Biol. 2014;15(12):550
pubmed: 25516281
Front Immunol. 2018 Apr 30;9:924
pubmed: 29780385
Crit Care. 2018 Mar 15;22(1):68
pubmed: 29540208
J Control Release. 2019 Jan 28;294:43-52
pubmed: 30529727
PLoS One. 2012;7(6):e38885
pubmed: 22719975
Intern Med J. 2019 Feb;49(2):160-170
pubmed: 30754087
Clin Biochem. 2020 Jan;75:30-34
pubmed: 31672649
Eur Respir J. 2011 Jun;37(6):1439-46
pubmed: 21071473
Thorax. 2003 May;58(5):377-82
pubmed: 12728155
Eur J Clin Microbiol Infect Dis. 2020 Feb;39(2):299-307
pubmed: 31758443
Lancet Respir Med. 2019 Jan;7(1):10-11
pubmed: 30442586
N Engl J Med. 2017 Aug 10;377(6):562-572
pubmed: 28792873
Clin Chest Med. 2018 Dec;39(4):691-701
pubmed: 30390742
Tumour Biol. 2016 Oct 14;:
pubmed: 27743380
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Am J Transl Res. 2017 Mar 15;9(3):1287-1296
pubmed: 28386354
J Cell Mol Med. 2020 Oct;24(20):12054-12064
pubmed: 32916773
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
Allergy. 2020 Feb;75(2):346-356
pubmed: 31386204
N Engl J Med. 2014 Oct 23;371(17):1619-28
pubmed: 25337751
JAMA. 2016 Feb 23;315(8):775-87
pubmed: 26903336
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Trends Mol Med. 2018 Nov;24(11):963-975
pubmed: 30244822
Exp Ther Med. 2017 Apr;13(4):1235-1244
pubmed: 28413462
Lancet Respir Med. 2016 Apr;4(4):259-71
pubmed: 26917434
J Extracell Vesicles. 2018 Dec 18;8(1):1555410
pubmed: 30574280